Post by Uncle on Jan 9, 2023 18:47:12 GMT
SKYTROFA® (lonapegsomatropin-tcgd) U.S preliminary, unaudited fourth quarter 2022 revenue is expected to be approximately €17.1 million. This includes an estimated negative foreign currency translation impact of €0.4 million, compared to a benefit of €0.5 million in the third quarter of 2022.
First European SKYTROFA® (lonapegsomatropin) commercial launch planned in Germany for the third quarter of 2023.
REF:
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 01/09/2023 - 7:00 AM
www.sec.gov/Archives/edgar/data/1612042/000119312523004171/d406271d6k.htm
Note# €17.1 million = 18,377,284.50 United States Dollar
First Quarter 2022 Financial Results €1.9 million commercial SKYTROFA sales
Second Quarter 2022 €4.4 million commercial SKYTROFA sales
Third Quarter 2022 €12.3 million commercial SKYTROFA sales
Fourth Quarter 2022 €17.1 million commercial SKYTROFA sales
2022 Total Sales
€35.7 million (38,365,362.00 United States Dollar)
In-Retrospect
August 27, 2021
Evaluate Vantage
"Meanwhile, approval of Ascendis's lonapegsomatropin, now branded Skytrofa, marks the first FDA green light for the group. Skytrofa is expected to be one of the biggest drug approvals in 2021, with 2026 sales forecast to reach $1.5bn in paediatric patients with growth hormone deficiency."
COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND), announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd).
First European SKYTROFA® (lonapegsomatropin) commercial launch planned in Germany for the third quarter of 2023.
REF:
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 01/09/2023 - 7:00 AM
www.sec.gov/Archives/edgar/data/1612042/000119312523004171/d406271d6k.htm
Note# €17.1 million = 18,377,284.50 United States Dollar
First Quarter 2022 Financial Results €1.9 million commercial SKYTROFA sales
Second Quarter 2022 €4.4 million commercial SKYTROFA sales
Third Quarter 2022 €12.3 million commercial SKYTROFA sales
Fourth Quarter 2022 €17.1 million commercial SKYTROFA sales
2022 Total Sales
€35.7 million (38,365,362.00 United States Dollar)
In-Retrospect
August 27, 2021
Evaluate Vantage
"Meanwhile, approval of Ascendis's lonapegsomatropin, now branded Skytrofa, marks the first FDA green light for the group. Skytrofa is expected to be one of the biggest drug approvals in 2021, with 2026 sales forecast to reach $1.5bn in paediatric patients with growth hormone deficiency."
COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND), announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd).
